Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

vancomycin use ≥ 3days
age 18-85years old
vancomycin use ≥ 3days
age 18-85years old

Exclusion Criteria

age <18years old or >85 years old
vancomycin use < 3days
age <18years old or >85 years old
vancomycin use < 3days

Summary

Conditions
Arbitrary Restriction Polymorphism 1
Type
Observational
Design
  • Observational Model: Case-Control
  • Time Perspective: Retrospective

Participation Requirements

Age
Between 18 years and 85 years
Gender
Both males and females

Description

The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent. After reviewing more than 6000 clinical charts of patients who received vancomycin therapy and whose serum vancomycin level was monitored between...

The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent. After reviewing more than 6000 clinical charts of patients who received vancomycin therapy and whose serum vancomycin level was monitored between January 2010 and December 2013, we identified 212 patients who also had diagnosed as severe acute pancreatitis (SAP group), and 98 patients who also had diagnosed as pneumonia (pneumonia group) at that time. The fluorescence polarization immunoassay method was used to measure vancomycin serum trough concentrations in these patients 30 min before the next administration. Using these measurements, we calculated the pharmacokinetic parameters using the Bayesian estimator.

Inclusion Criteria

vancomycin use ≥ 3days
age 18-85years old
vancomycin use ≥ 3days
age 18-85years old

Exclusion Criteria

age <18years old or >85 years old
vancomycin use < 3days
age <18years old or >85 years old
vancomycin use < 3days

Tracking Information

NCT #
NCT02134665
Collaborators
Not Provided
Investigators
Study Director: Wan-Hua Yang, Prof. Ruijin Hospital